G. Jayson, E. Kohn, H. Kitchener, and J. Ledermann, Ovarian cancer, The Lancet, vol.384, issue.9951, 2014.
DOI : 10.1016/S0140-6736(13)62146-7

A. Jemal, F. Bray, M. Center, J. Ferlay, E. Ward et al., CA: a cancer journal for clinicians, Global cancer statistics, pp.69-90, 2011.

T. Perren, A. Swart, J. Pfisterer, J. Ledermann, E. Pujade-lauraine et al., A Phase 3 Trial of Bevacizumab in Ovarian Cancer, New England Journal of Medicine, vol.365, issue.26, pp.2484-96, 2011.
DOI : 10.1056/NEJMoa1103799

R. Naumann and R. Coleman, Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer, Drugs, vol.18, issue.1, pp.1397-412, 2011.
DOI : 10.1016/j.ygyno.2007.08.092

H. Risch, J. Mclaughlin, D. Cole, B. Rosen, L. Bradley et al., Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin-Cohort Study in Ontario, Canada, JNCI Journal of the National Cancer Institute, vol.98, issue.23, pp.1694-706, 2006.
DOI : 10.1093/jnci/djj465

S. Chen, E. Iversen, T. Friebel, D. Finkelstein, B. Weber et al., Mutations in a Large United States Sample, Journal of Clinical Oncology, vol.24, issue.6, pp.863-71, 2006.
DOI : 10.1200/JCO.2005.03.6772

B. Hennessy, R. Coleman, and M. Markman, Ovarian cancer, The Lancet, vol.374, issue.9698, pp.1371-82, 2009.
DOI : 10.1016/S0140-6736(09)61338-6

H. Lynch, M. Casey, C. Snyder, C. Bewtra, J. Lynch et al., Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management, Molecular Oncology, vol.98, issue.Suppl. 1, pp.97-137, 2009.
DOI : 10.1016/S0301-2115(01)00318-9
URL : http://onlinelibrary.wiley.com/doi/10.1016/j.molonc.2009.02.004/pdf

A. Bashashati, G. Ha, A. Tone, J. Ding, L. Prentice et al., Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling, The Journal of Pathology, vol.10, issue.1, pp.21-34, 2013.
DOI : 10.1158/0008-5472.CAN-12-0203
URL : http://onlinelibrary.wiley.com/doi/10.1002/path.4230/pdf

R. Kurman, S. Ie, and M. , Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer???Shifting the paradigm, Human Pathology, vol.42, issue.7, pp.918-949, 2011.
DOI : 10.1016/j.humpath.2011.03.003

S. Banerjee and S. Kaye, New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential, Clinical Cancer Research, vol.19, issue.5, pp.961-969, 2013.
DOI : 10.1158/1078-0432.CCR-12-2243

D. Yang, S. Khan, Y. Sun, K. Hess, I. Shmulevich et al., Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer, JAMA, vol.306, issue.14, pp.1557-65, 2011.
DOI : 10.1001/jama.2011.1456

J. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. Vergote et al., Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer, Obstetrical & Gynecological Survey, vol.69, issue.10, pp.852-61, 2014.
DOI : 10.1097/OGX.0000000000000107

G. Konecny, C. Wang, H. Hamidi, B. Winterhoff, K. Kalli et al., Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer 2014;106. and survival in ovarian, fallopian tube, and peritoneal carcinomas, J Natl Cancer Inst. Clin Cancer Res, vol.20, pp.764-75, 2014.

T. Popova, E. Manie, G. Rieunier, V. Caux-moncoutier, C. Tirapo et al., Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation, Cancer Research, vol.72, issue.21, pp.5454-62, 2012.
DOI : 10.1158/0008-5472.CAN-12-1470
URL : http://cancerres.aacrjournals.org/content/canres/72/21/5454.full.pdf

S. Topalian, J. Taube, R. Anders, and D. Pardoll, Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy, Nature Reviews Cancer, vol.344, issue.5, pp.275-87, 2016.
DOI : 10.1126/science.270.5238.985
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381938

J. Hamanishi, M. Mandai, T. Ikeda, M. Minami, A. Kawaguchi et al., Safety and Antitumor Activity of Anti???PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer, Journal of Clinical Oncology, vol.33, issue.34, pp.4015-4037, 2015.
DOI : 10.1200/JCO.2015.62.3397